Company Profile For Actelion Ltd

Actelion Ltd is a Swiss biopharmaceutical company with a global presence that focuses on the discovery, development and commercialization of treatments to serve unmet medical needs. Its products specialize in conditions related to the endothelium, the single layer of cells separating every blood vessel from the blood stream. The Company has three approved drugs on the market. Tracleer, an orally available dual endothelin receptor antagonist, has been approved as a therapy for pulmonary arterial hypertension, a chronic, life-threatening disorder that severely compromises the functions of the lungs and heart. The second product, Zavesca, was in-licensed from Oxford GlycoSciences. Zavesca is an approved oral treatment for type 1 Gaucher disease, a rare debilitating metabolic disorder. Ventavis, the third product, is an inhaled synthetic analogue of prostacyclin that produces potent pulmonary vasodilation and inhibits platelet aggregation, among other benefits.

BRIEF: For the nine months ended 30 September 2009, Actelion Ltd's total revenue increased 22% to SF1.3B. Net income for the period increased 44% to SF326.9M. Total revenue reflects an increase in demand for the Company's products and services as well as favorable market conditions. Net income for the period benefited from significantly higher positive financial result and a decrease in interest expense.

Actelion Ltd
Gewerbestrasse 16
Allschwil     4123
P: +4161.5656565
F: +4161.5656500

2000